ME03799B - Dijagnostički testovi i kompleti za detekciju folatnog receptora 1 - Google Patents

Dijagnostički testovi i kompleti za detekciju folatnog receptora 1

Info

Publication number
ME03799B
ME03799B MEP-2020-142A MEP2020142A ME03799B ME 03799 B ME03799 B ME 03799B ME P2020142 A MEP2020142 A ME P2020142A ME 03799 B ME03799 B ME 03799B
Authority
ME
Montenegro
Prior art keywords
kits
detection
diagnostic assays
folate receptor
folate
Prior art date
Application number
MEP-2020-142A
Other languages
German (de)
English (en)
French (fr)
Inventor
Nathan E Testa
Christina N Carrigan
Olga Ab
Daniel Tavares
Beni B Wolf
Original Assignee
Immunogen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunogen Inc filed Critical Immunogen Inc
Publication of ME03799B publication Critical patent/ME03799B/me

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3015—Breast
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3023—Lung
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/303—Liver or Pancreas
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Oncology (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
MEP-2020-142A 2012-08-31 2013-08-30 Dijagnostički testovi i kompleti za detekciju folatnog receptora 1 ME03799B (me)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201261695791P 2012-08-31 2012-08-31
US201361756254P 2013-01-24 2013-01-24
EP13833526.0A EP2890717B1 (en) 2012-08-31 2013-08-30 Diagnostic assays and kits for detection of folate receptor 1
PCT/US2013/057682 WO2014036495A2 (en) 2012-08-31 2013-08-30 Diagnostic assays and kits for detection of folate receptor 1

Publications (1)

Publication Number Publication Date
ME03799B true ME03799B (me) 2021-04-20

Family

ID=50184673

Family Applications (1)

Application Number Title Priority Date Filing Date
MEP-2020-142A ME03799B (me) 2012-08-31 2013-08-30 Dijagnostički testovi i kompleti za detekciju folatnog receptora 1

Country Status (27)

Country Link
US (6) US9200073B2 (me)
EP (2) EP3712175A1 (me)
JP (6) JP6293147B2 (me)
KR (4) KR102617499B1 (me)
CN (2) CN110294805B (me)
AU (4) AU2013308497B2 (me)
BR (1) BR112015004229B1 (me)
CA (2) CA2883222C (me)
CY (1) CY1122907T1 (me)
DK (1) DK2890717T3 (me)
ES (1) ES2788151T3 (me)
HK (1) HK1210188A1 (me)
HR (1) HRP20200482T1 (me)
HU (1) HUE049693T2 (me)
IL (4) IL299620A (me)
LT (1) LT2890717T (me)
ME (1) ME03799B (me)
MX (1) MX362514B (me)
NZ (2) NZ726258A (me)
PL (1) PL2890717T3 (me)
PT (1) PT2890717T (me)
RS (1) RS60217B1 (me)
RU (1) RU2668824C2 (me)
SG (2) SG10201804260QA (me)
SI (1) SI2890717T1 (me)
WO (1) WO2014036495A2 (me)
ZA (1) ZA201707245B (me)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20220017432A (ko) 2010-02-24 2022-02-11 이뮤노젠 아이엔씨 엽산염 수용체 1 항체와 면역접합체 및 이들의 용도
CA3182262A1 (en) 2011-04-01 2012-10-04 Immunogen, Inc. Methods for increasing efficacy of folr1 cancer therapy
SG10201804260QA (en) 2012-08-31 2018-07-30 Immunogen Inc Diagnostic assays and kits for detection of folate receptor 1
JP6383787B2 (ja) * 2013-06-20 2018-08-29 モルフォテック， インコーポレイテッド 卵巣癌の治療方法
SG10201907501QA (en) 2013-08-30 2019-10-30 Immunogen Inc Antibodies and assays for detection of folate receptor 1
PT3653228T (pt) * 2013-10-08 2024-07-17 Immunogen Inc Regimes de dosagem de imunoconjugado anti-folr1
US20150297744A1 (en) * 2014-03-28 2015-10-22 Immunogen, Inc. Anti-FOLR1 Immunoconjugate Dosing Regimens
EP3153178A4 (en) * 2014-06-06 2017-12-20 Kyowa Hakko Kirin Co., Ltd. Method for treating cancer patients using folr1 targeted drug and antifolate, and drug
KR102648966B1 (ko) * 2014-11-20 2024-03-19 에프. 호프만-라 로슈 아게 Folr1 및 cd3에 대한 t 세포 활성화 이중특이적 항원 결합 분자
CN108601828B (zh) 2015-09-17 2023-04-28 伊缪诺金公司 包含抗folr1免疫缀合物的治疗组合
CN105548059B (zh) * 2016-01-29 2018-08-24 福建医科大学 叶酸-牛血清白蛋白-铂铋纳米复合材料
WO2017192863A1 (en) 2016-05-04 2017-11-09 L.E.A.F. Holdings Group Llc Targeted liposomal gemcitabine compositions and methods thereof
US10822410B2 (en) 2016-11-23 2020-11-03 Eisai R&D Management Co., Ltd. Anti-folate receptor alpha antibodies and uses thereof
CN108982430B (zh) * 2017-05-31 2020-09-29 北京大学 标记细菌菌群样品的试剂盒、方法及应用
KR20240034260A (ko) * 2017-09-05 2024-03-13 이뮤노젠 아이엔씨 환자 샘플에서 엽산 수용체 1의 검출 방법
AU2019236091A1 (en) * 2018-03-13 2020-09-03 Phanes Therapeutics, Inc. Anti-folate receptor 1 antibodies and uses thereof
KR20210151173A (ko) * 2019-04-12 2021-12-13 페인스 테라퓨틱스 인코포레이티드 인간화된 항-폴레이트 수용체 1 키메라 항원 수용체 및 그의 용도
SG11202111109UA (en) 2019-04-29 2021-11-29 Immunogen Inc Biparatopic fr-alpha antibodies and immunoconjugates
CN112794911B (zh) * 2021-04-14 2021-08-03 上海偌妥生物科技有限公司 人源化抗叶酸受体1抗体及其应用
CN114163520B (zh) * 2021-11-23 2024-01-30 南京京达生物技术有限公司 一种血源性人IgM抗体纯化介质制备方法
WO2023116911A1 (zh) 2021-12-24 2023-06-29 百奥泰生物制药股份有限公司 抗FRα抗体及其抗体药物偶联物和用途
CN117700556B (zh) * 2024-02-05 2024-04-12 苏州百道医疗科技有限公司 一种抗FRα小鼠单克隆抗体及其应用
CN117700557B (zh) * 2024-02-05 2024-04-30 卡秋(江苏)生物科技有限公司 一种特异性结合叶酸受体α的抗体或抗原结合片段

Family Cites Families (153)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3645090A (en) 1969-06-19 1972-02-29 Citizen Watch Co Ltd Day-date quick-adjuster for calender timepiece
US3940475A (en) 1970-06-11 1976-02-24 Biological Developments, Inc. Radioimmune method of assaying quantitatively for a hapten
US4588585A (en) 1982-10-19 1986-05-13 Cetus Corporation Human recombinant cysteine depleted interferon-β muteins
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
DE3590766T (me) 1985-03-30 1987-04-23
US6492107B1 (en) 1986-11-20 2002-12-10 Stuart Kauffman Process for obtaining DNA, RNA, peptides, polypeptides, or protein, by recombinant DNA technique
US4737456A (en) 1985-05-09 1988-04-12 Syntex (U.S.A.) Inc. Reducing interference in ligand-receptor binding assays
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US5618920A (en) 1985-11-01 1997-04-08 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
DE3600905A1 (de) 1986-01-15 1987-07-16 Ant Nachrichtentech Verfahren zum dekodieren von binaersignalen sowie viterbi-dekoder und anwendungen
US5681718A (en) 1986-03-14 1997-10-28 Celltech Limited Methods for enhanced production of tissue plasminogen activator in cell culture using alkanoic acids or salts thereof
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
WO1989006692A1 (en) 1988-01-12 1989-07-27 Genentech, Inc. Method of treating tumor cells by inhibiting growth factor receptor function
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
GB8826530D0 (en) 1988-11-12 1988-12-14 Ped Capacitors Ltd Electrical capacitors
US20040049014A1 (en) 1988-12-28 2004-03-11 Protein Design Labs, Inc. Humanized immunoglobulins
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5108921A (en) 1989-04-03 1992-04-28 Purdue Research Foundation Method for enhanced transmembrane transport of exogenous molecules
CA2016842A1 (en) 1989-05-16 1990-11-16 Richard A. Lerner Method for tapping the immunological repertoire
CA2016841C (en) 1989-05-16 1999-09-21 William D. Huse A method for producing polymers having a preselected activity
CA2057923A1 (en) 1989-05-16 1990-11-17 William D. Huse Co-expression of heteromeric receptors
JP3068180B2 (ja) 1990-01-12 2000-07-24 アブジェニックス インコーポレイテッド 異種抗体の生成
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US6916605B1 (en) 1990-07-10 2005-07-12 Medical Research Council Methods for producing members of specific binding pairs
AU8505191A (en) 1990-08-24 1992-03-17 Ixsys, Inc. Methods of synthesizing oligonucleotides with random codons
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
ATE158021T1 (de) 1990-08-29 1997-09-15 Genpharm Int Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
DK0564531T3 (da) 1990-12-03 1998-09-28 Genentech Inc Berigelsesfremgangsmåde for variantproteiner med ændrede bindingsegenskaber
JP3298879B2 (ja) 1990-12-20 2002-07-08 イグジス，インコーポレイテッド 結合タンパク質の最適化
WO1993006213A1 (en) 1991-09-23 1993-04-01 Medical Research Council Production of chimeric antibodies - a combinatorial approach
PT1024191E (pt) 1991-12-02 2008-12-22 Medical Res Council Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
CA2103887C (en) 1991-12-13 2005-08-30 Gary M. Studnicka Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof
US5965132A (en) 1992-03-05 1999-10-12 Board Of Regents, The University Of Texas System Methods and compositions for targeting the vasculature of solid tumors
CA2452130A1 (en) 1992-03-05 1993-09-16 Francis J. Burrows Methods and compositions for targeting the vasculature of solid tumors
US20030148406A1 (en) 1992-03-17 2003-08-07 David John King Multivalent antigen-binding proteins
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
AU6132994A (en) 1993-02-02 1994-08-29 Scripps Research Institute, The Methods for producing antibody libraries using universal or randomized immunoglobulin light chains
CA2163345A1 (en) 1993-06-16 1994-12-22 Susan Adrienne Morgan Antibodies
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
DE69637481T2 (de) 1995-04-27 2009-04-09 Amgen Fremont Inc. Aus immunisierten Xenomäusen stammende menschliche Antikörper gegen IL-8
AU2466895A (en) 1995-04-28 1996-11-18 Abgenix, Inc. Human antibodies derived from immunized xenomice
CA2229043C (en) 1995-08-18 2016-06-07 Morphosys Gesellschaft Fur Proteinoptimierung Mbh Protein/(poly)peptide libraries
US6696248B1 (en) 1995-08-18 2004-02-24 Morphosys Ag Protein/(poly)peptide libraries
AU7378096A (en) 1995-09-28 1997-04-17 Alexion Pharmaceuticals, Inc. Porcine cell interaction proteins
US6331431B1 (en) 1995-11-28 2001-12-18 Ixsys, Inc. Vacuum device and method for isolating periplasmic fraction from cells
US5714352A (en) 1996-03-20 1998-02-03 Xenotech Incorporated Directed switch-mediated DNA recombination
KR20080059467A (ko) 1996-12-03 2008-06-27 아브게닉스, 인크. 복수의 ｖｈ 및 ｖｋ 부위를 함유하는 사람 면역글로불린유전자좌를 갖는 형질전환된 포유류 및 이로부터 생성된항체
US6596850B1 (en) 1998-01-30 2003-07-22 Ixsys, Incorporated Anti-αv3β3 recombinant human antibodies, nucleic acids encoding same
WO1999006834A2 (en) 1997-08-04 1999-02-11 Ixsys, Incorporated Methods for identifying ligand specific binding molecules
EP1150688A4 (en) 1998-10-19 2004-06-16 Yeda Res & Dev TREATING SYSTEMIC LUPUS ERYTHEMATODES BY REGULATING THE AUTOIMMUNE RESPONSE TO AUTOANTIGENS
US20040031072A1 (en) 1999-05-06 2004-02-12 La Rosa Thomas J. Soy nucleic acid molecules and other molecules associated with transcription plants and uses thereof for plant improvement
JP4794789B2 (ja) 1999-07-02 2011-10-19 モルフォシス・アクチェンゲゼルシャフト ゲノムｄｎａ断片またはｅｓｔによってコードされる（ポリ）ペプチドに対する特異的結合パートナーの作成
IT1307309B1 (it) 1999-12-30 2001-10-30 Enea Ente Nuove Tec Peptidi stabilizzanti, polipeptidi ed anticorpi che li comprendono.
HUP0300421A2 (hu) 2000-03-31 2003-06-28 Purdue Research Foundation Kezelési eljárás ligand-immunogén konjugátumok felhasználásával
DE10037759A1 (de) 2000-08-03 2002-07-04 Gruenenthal Gmbh Screeningverfahren
WO2002069232A2 (en) 2001-02-19 2002-09-06 Merck Patent Gmbh Method for identification of t-cell epitopes and use for preparing molecules with reeduced immunogenicity
WO2002071928A2 (en) 2001-03-14 2002-09-19 Millennium Pharmaceuticals, Inc. Nucleic acid molecules and proteins for the identification, assessment, prevention, and therapy of ovarian cancer
CN101979095A (zh) 2001-05-02 2011-02-23 普渡研究基金会 巨噬细胞介导的疾病的治疗和诊断
US7314974B2 (en) 2002-02-21 2008-01-01 Monsanto Technology, Llc Expression of microbial proteins in plants for production of plants with improved properties
AU2003211337A1 (en) 2002-03-01 2003-09-16 Japan Envirochemicals, Ltd. Proteins capable of binding to female sex hormones and process for producing the same
AU2003224073C1 (en) 2002-04-22 2010-03-11 AgroProtect GmbH Antibodies, recombinant antibodies, recombinant antibody fragments and fusions mediated plant disease resistance against fungi
US7538195B2 (en) 2002-06-14 2009-05-26 Immunogen Inc. Anti-IGF-I receptor antibody
GB0216648D0 (en) 2002-07-18 2002-08-28 Lonza Biologics Plc Method of expressing recombinant protein in CHO cells
CA2504818C (en) 2002-11-07 2013-04-23 Immunogen, Inc. Anti-cd33 antibodies and method for treatment of acute myeloid leukemia using the same
AU2003295411A1 (en) 2002-11-07 2004-06-03 Celltech R & D Human monoclonal antibodies to heparanase
EP1481993A1 (en) 2003-05-28 2004-12-01 Xerion Pharmaceuticals AG Modulation of the poliovirus receptor function
US20050255114A1 (en) 2003-04-07 2005-11-17 Nuvelo, Inc. Methods and diagnosis for the treatment of preeclampsia
US20050025763A1 (en) 2003-05-08 2005-02-03 Protein Design Laboratories, Inc. Therapeutic use of anti-CS1 antibodies
AU2004252067B2 (en) 2003-05-09 2012-04-12 Duke University CD20-specific antibodies and methods of employing same
EP2281577B1 (en) 2003-05-14 2016-11-16 ImmunoGen, Inc. Drug conjugate composition
US7276497B2 (en) 2003-05-20 2007-10-02 Immunogen Inc. Cytotoxic agents comprising new maytansinoids
ZA200510282B (en) 2003-07-02 2007-03-28 Genentech Inc Compositions and methods for the diagnosis and treatment of tumor
WO2005054469A1 (en) 2003-12-05 2005-06-16 Her Majesty The Queen In Right Of Canada As Represented By The Minister Of Health Anti-sars monoclonal antibodies
JP4805848B2 (ja) * 2004-02-12 2011-11-02 モルフォテック、インク． 腫瘍抗原の生物活性を特異的に阻止するモノクローナル抗体
US20080187954A1 (en) 2004-03-10 2008-08-07 Lonza Ltd. Method For Producing Antibodies
JP5128273B2 (ja) 2004-04-27 2013-01-23 ガラパゴス・ナムローゼ・フェンノートシャップ 未分化哺乳動物細胞の分化を骨芽細胞へと誘導するための方法、作用物質、及び化合物スクリーニングアッセイ
US20080312425A1 (en) 2004-08-30 2008-12-18 Lonza Biologics Plc. Ion Exchange Chromatography and Purification of Antibodies
US7776869B2 (en) 2004-10-18 2010-08-17 Amgen Inc. Heteroaryl-substituted alkyne compounds and method of use
AU2005306997B2 (en) 2004-10-25 2012-07-05 Merck Sharp & Dohme Corp. Anti-ADDL antibodies and uses thereof
US20070294782A1 (en) 2004-12-21 2007-12-20 Mark Abad Transgenic plants with enhanced agronomic traits
AU2005323025A1 (en) 2004-12-31 2006-07-13 Biogen Idec Ma Inc. Polypeptides that bind BR3 and uses thereof
CA2594297A1 (en) 2005-01-27 2006-07-27 The Regents Of The University Of California Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins
US7608413B1 (en) 2005-03-25 2009-10-27 Celera Corporation Kidney disease targets and uses thereof
DK1866339T3 (da) 2005-03-25 2013-09-02 Gitr Inc GTR-bindende molekyler og anvendelser heraf
US20090081710A1 (en) 2005-03-30 2009-03-26 Purdue Research Foundation Method for Cancer Prognosis Using Cellular Folate Vitamin Receptor Quantification
WO2006116592A2 (en) 2005-04-22 2006-11-02 Morphotek, Inc. Antibodies with immune effector activity and that internalize in folate receptor alpha-positive cells
EP1888639A1 (en) 2005-05-12 2008-02-20 Oncotherapy Science, Inc. Methods for damaging cells using effector function of anti-dsc2 antibody
ES2864039T3 (es) 2005-05-20 2021-10-13 Lonza Biologics Plc Expresión de alto nivel de un anticuerpo recombinante en una célula huésped de mamífero
BRPI0610203A2 (pt) 2005-05-24 2010-06-01 Avestha Gengraine Tech Pvt Ltd processo de preparação in vivo de anti-corpo monoclonal anti-cd 20 biologicamente ativo e composição farmacêutica
EP1904183B1 (en) 2005-07-05 2014-10-15 Purdue Research Foundation Pharmaceutical composition for the treatment of osteoarthritis
US7521195B1 (en) 2005-07-21 2009-04-21 Celera Corporation Lung disease targets and uses thereof
EP1937720B1 (en) 2005-08-18 2014-04-09 Ramot at Tel-Aviv University Ltd. Single chain antibodies against beta-amyloid peptide
ES2543341T3 (es) 2005-09-13 2015-08-18 National Research Council Of Canada Métodos y composiciones para modular la actividad de células tumorales
AU2006304605A1 (en) 2005-10-17 2007-04-26 Institute For Systems Biology Tissue-and serum-derived glycoproteins and methods of their use
EP1790664A1 (en) 2005-11-24 2007-05-30 Ganymed Pharmaceuticals AG Monoclonal antibodies against claudin-18 for treatment of cancer
ES2526079T3 (es) 2005-12-20 2015-01-05 Sbi Biotech Co., Ltd. Anticuerpo anti-ILT7
CA2685300C (en) 2006-06-01 2017-01-03 Mayo Foundation For Medical Education And Research Immunity to folate receptors
EP3231442B1 (en) 2006-06-23 2019-12-25 ADC Therapeutics SA Polynucleotides and polypeptide sequences involved in cancer
US7910702B2 (en) 2006-07-28 2011-03-22 The Governors Of The University Of Alberta Recombinant antibodies to sclerotinia antigens
AU2007284651B2 (en) 2006-08-09 2014-03-20 Institute For Systems Biology Organ-specific proteins and methods of their use
US20090182955A1 (en) 2006-09-08 2009-07-16 Rao Cherukuri Application configuration across client devices of a local system
EP1900752A1 (en) * 2006-09-15 2008-03-19 DOMPE' pha.r.ma s.p.a. Human anti-folate receptor alpha antibodies and antibody fragments for the radioimmunotherapy of ovarian carcinoma
RU2537245C2 (ru) 2006-10-12 2014-12-27 Чугаи Сейяку Кабусики Кайся Диагностика и лечение злокачественной опухоли с использованием антитела против ereg
CA2672581A1 (en) 2006-12-14 2008-06-19 Forerunner Pharma Research Co., Ltd. Anti-claudin 3 monoclonal antibody and treatment and diagnosis of cancer using the same
US8465741B2 (en) 2006-12-20 2013-06-18 Mmrglobal, Inc. Antibodies and methods for making and using them
US20080227704A1 (en) 2006-12-21 2008-09-18 Kamens Joanne S CXCL13 binding proteins
US7691980B2 (en) 2007-01-09 2010-04-06 Bio-Rad Laboratories, Inc. Enhanced capacity and purification of antibodies by mixed mode chromatography in the presence of aqueous-soluble nonionic organic polymers
EP2604284A1 (en) 2007-02-16 2013-06-19 KTB Tumorforschungsgesellschaft mbH Receptor And Antigen Targeted Prodrug
WO2008101231A2 (en) 2007-02-16 2008-08-21 Endocyte, Inc. Methods and compositions for treating and diagnosing kidney disease
WO2008145136A1 (en) 2007-05-30 2008-12-04 Aarhus Universitet Stat3 inactivation by inhibition of the folate receptor pathway
CN101784565B (zh) 2007-06-25 2014-12-10 恩多塞特公司 含有亲水性间隔区接头的共轭物
CN101139613B (zh) 2007-08-01 2011-06-08 姜荣锡 抗肿瘤二元多肽及其应用与制备方法
WO2009080759A1 (en) 2007-12-21 2009-07-02 Novartis Ag Organic compounds
CA2711557A1 (en) 2008-01-11 2009-07-16 The University Of Tokyo Anti-cldn6 antibody
EP2238154B1 (en) 2008-01-18 2015-09-16 Bio-Rad Laboratories, Inc. Enhanced purification of phosphorylated and non-phosphorylated biomolecules by apatite chromatography
JP5470817B2 (ja) 2008-03-10 2014-04-16 日産自動車株式会社 電池用電極およびこれを用いた電池、並びにその製造方法
EP2288428A2 (en) 2008-04-21 2011-03-02 Swapsol Corp. Hydrogen sulfide conversion to hydrogen
WO2009132081A2 (en) 2008-04-24 2009-10-29 The Research Foundation Of State University Of New York Monoclonal antibody-based targeting of folate receptors
EP2276506A4 (en) 2008-04-30 2014-05-07 Immunogen Inc EFFICIENT CONJUGATES AND HYDROPHILIC BINDER
US8236319B2 (en) 2008-04-30 2012-08-07 Immunogen, Inc. Cross-linkers and their uses
US8383351B2 (en) 2008-06-11 2013-02-26 Oxford Brookes University Antibody to inhibin/ activin β-B subunit
US20100069298A1 (en) * 2008-09-16 2010-03-18 Robert Penny Methods for Detecting Overexpression of SPARC and Therapeutic and Diagnostic Methods Relating to Same
WO2010033733A1 (en) 2008-09-17 2010-03-25 Endocyte, Inc. Folate receptor binding conjugates of antifolates
US20100092470A1 (en) 2008-09-22 2010-04-15 Icb International, Inc. Antibodies, analogs and uses thereof
CN101440130B (zh) 2008-11-21 2011-07-27 中国人民解放军第四军医大学 一种抗人IL-13Rα2单克隆抗体的重链和轻链的可变区
JP5923035B2 (ja) 2009-03-24 2016-05-24 バイオセプト インコーポレイティッド 細胞の捕捉および解析のデバイスおよび方法
CN102574915B (zh) * 2009-08-06 2014-10-22 伊缪纳斯制药株式会社 特异性结合Aβ寡聚体的抗体及其用途
TW201129383A (en) 2010-02-10 2011-09-01 Immunogen Inc CD20 antibodies and uses thereof
KR20220017432A (ko) 2010-02-24 2022-02-11 이뮤노젠 아이엔씨 엽산염 수용체 1 항체와 면역접합체 및 이들의 용도
EP2629798A4 (en) * 2010-10-20 2014-05-28 Morphotek Inc GLYCOFORMS OF ANTI-RECEPTOR ANTIBODY-ALPHA FOLATE (ANTI-FRA)
AU2011323124C1 (en) * 2010-11-05 2016-09-22 Eisai Inc. Folate receptor alpha as a diagnostic and prognostic marker for folate receptor alpha-expressing cancers
KR102272828B1 (ko) 2011-03-29 2021-07-05 이뮤노젠 아이엔씨 일-단계 방법에 의한 메이탄시노이드 항체 접합체의 제조
EP2691117A2 (en) 2011-03-29 2014-02-05 Immunogen, Inc. Process for manufacturing conjugates of improved homogeneity
CA3182262A1 (en) 2011-04-01 2012-10-04 Immunogen, Inc. Methods for increasing efficacy of folr1 cancer therapy
US20120282282A1 (en) 2011-04-04 2012-11-08 Immunogen, Inc. Methods for Decreasing Ocular Toxicity of Antibody Drug Conjugates
DK2731972T3 (en) 2011-07-15 2018-03-12 Eisai R&D Man Co Ltd Antifolate receptor alpha antibodies and uses thereof
SG10201804260QA (en) 2012-08-31 2018-07-30 Immunogen Inc Diagnostic assays and kits for detection of folate receptor 1
KR20150094617A (ko) 2012-12-07 2015-08-19 교와 핫꼬 기린 가부시키가이샤 항 ｆｏｌｒ１ 항체
JP6136279B2 (ja) 2013-01-15 2017-05-31 株式会社ジェイテクト 転がり軸受装置
TWI503850B (zh) 2013-03-22 2015-10-11 Polytronics Technology Corp 過電流保護元件
JP2016520082A (ja) 2013-05-14 2016-07-11 イミュノジェン， インコーポレイテッド 抗ｆｏｌｒ１免疫複合体投与計画
SG10201907501QA (en) 2013-08-30 2019-10-30 Immunogen Inc Antibodies and assays for detection of folate receptor 1
TWI510996B (zh) 2013-10-03 2015-12-01 Acer Inc 控制觸控面板的方法以及使用該方法的可攜式電腦
PT3653228T (pt) 2013-10-08 2024-07-17 Immunogen Inc Regimes de dosagem de imunoconjugado anti-folr1
US20150297744A1 (en) 2014-03-28 2015-10-22 Immunogen, Inc. Anti-FOLR1 Immunoconjugate Dosing Regimens
CN108601828B (zh) 2015-09-17 2023-04-28 伊缪诺金公司 包含抗folr1免疫缀合物的治疗组合
US9816280B1 (en) 2016-11-02 2017-11-14 Matthew Reitnauer Portable floor

Also Published As

Publication number Publication date
CA2883222C (en) 2021-12-14
AU2023210668A1 (en) 2023-08-31
CN104755498B (zh) 2019-06-18
NZ630433A (en) 2017-10-27
MX2015002605A (es) 2015-06-10
KR20210145850A (ko) 2021-12-02
JP6480558B2 (ja) 2019-03-13
ES2788151T3 (es) 2020-10-20
IL280634A (en) 2021-03-25
US20200333347A1 (en) 2020-10-22
RS60217B1 (sr) 2020-06-30
LT2890717T (lt) 2020-06-10
HUE049693T2 (hu) 2020-10-28
RU2018133493A (ru) 2020-03-24
EP2890717A4 (en) 2016-08-03
CY1122907T1 (el) 2021-10-29
EP2890717A2 (en) 2015-07-08
JP2015533788A (ja) 2015-11-26
IL280634B2 (en) 2023-06-01
US20190227073A1 (en) 2019-07-25
US10180432B2 (en) 2019-01-15
CA2883222A1 (en) 2014-03-06
NZ726258A (en) 2019-07-26
DK2890717T3 (da) 2020-05-11
SG10201804260QA (en) 2018-07-30
PL2890717T3 (pl) 2020-08-10
US20230213524A1 (en) 2023-07-06
RU2668824C2 (ru) 2018-10-02
BR112015004229B1 (pt) 2023-02-07
SG11201500938XA (en) 2015-04-29
JP2020018325A (ja) 2020-02-06
KR20240005129A (ko) 2024-01-11
IL237087A0 (en) 2015-03-31
ZA201707245B (en) 2019-05-29
HRP20200482T1 (hr) 2020-06-26
WO2014036495A3 (en) 2014-04-10
KR20200079565A (ko) 2020-07-03
KR20150046316A (ko) 2015-04-29
AU2020204602B2 (en) 2023-08-24
IL299620A (en) 2023-03-01
JP2018088942A (ja) 2018-06-14
US10613093B2 (en) 2020-04-07
CN110294805A (zh) 2019-10-01
EP2890717B1 (en) 2020-03-04
JP2018042573A (ja) 2018-03-22
AU2013308497A1 (en) 2015-02-26
US20180003715A1 (en) 2018-01-04
US20140099332A1 (en) 2014-04-10
CN104755498A (zh) 2015-07-01
US9200073B2 (en) 2015-12-01
CN110294805B (zh) 2023-08-15
AU2018203934B2 (en) 2020-05-07
HK1210188A1 (en) 2016-04-15
AU2020204602A1 (en) 2020-07-30
JP2023111942A (ja) 2023-08-10
JP7289346B2 (ja) 2023-06-09
WO2014036495A4 (en) 2014-05-08
PT2890717T (pt) 2020-04-22
WO2014036495A2 (en) 2014-03-06
IL264770B (en) 2021-02-28
KR102617499B1 (ko) 2023-12-22
IL237087B (en) 2019-05-30
US20160146824A1 (en) 2016-05-26
MX362514B (es) 2019-01-22
EP3712175A1 (en) 2020-09-23
JP6293147B2 (ja) 2018-03-14
SI2890717T1 (sl) 2020-07-31
AU2013308497B2 (en) 2018-06-28
AU2018203934A1 (en) 2018-06-21
JP2022022420A (ja) 2022-02-03
BR112015004229A2 (pt) 2017-08-08
RU2015104579A (ru) 2016-10-20
US9702881B2 (en) 2017-07-11
CA3137438A1 (en) 2014-03-06

Similar Documents

Publication Publication Date Title
IL280634A (en) Tests and diagnostic kits for the detection of folate receptor 1
ZA201907806B (en) Antibodies and assays for detection of folate receptor 1
HK1204648A1 (en) Methods and devices for detection and measurement of analytes
EP2807479A4 (en) DEVICES AND METHODS FOR RAPIDLY AND PRECISELY DETECTING THE SUBSTANCES TO BE ANALYZED
FR2989810B1 (fr) Piece de revetement de sol pour la detection de chutes
GB201412804D0 (en) Automatic synthesis of unit tests for security testing
EP3014505A4 (en) Pathway analysis for identification of diagnostic tests
EP2873976A4 (en) DETECTION SYSTEM FOR A TEST SUBSTANCE
HK1206960A1 (en) Apparatuses for detecting and or diagnosing swallowing disorders
IL230693A0 (en) Use of the i-3859 antibody for the detection and diagnosis of cancer
EP2917331A4 (en) METHODS AND SYSTEMS FOR SENSITIVITY OF ENHANCED DETECTION OF ASSAYS
IL236436A0 (en) Kits and methods for the detection of cyanide
HK1204061A1 (en) Methods and kits for detecting and diagnosing neurotrauma
HK1205197A1 (en) Assays for detection of glycosaminoglycans
EP2800973A4 (en) METHOD AND COMPOUNDS FOR INCREASING THE SENSITIVITY OF BOTULINUM ASSAYS
EP2812694A4 (en) TESTS AND METHODS FOR DIAGNOSING OVARIAN CANCER
GB201203266D0 (en) Assay for the detection of the phenylpiperazine family
GB201216883D0 (en) Ultrasonic non-destructive testing of solid objects